HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs.

Abstract
Advanced stage neuroblastoma has a poor clinical outcome and microtubule-destabilizing agents, such as the Vinca alkaloids, are an important component in the treatment of this childhood cancer. Vinca alkaloids bind to beta-tubulin on the alpha/beta-tubulin heterodimer and disrupt microtubule dynamics, leading to cell death. To date, studies examining the contribution of microtubules and associated proteins to the efficacy of microtubule-destabilizing agents in neuroblastoma have been limited. In this study, BE2-C neuroblastoma cells previously selected for resistance to either vincristine (BE/VCR10) or colchicine (BE/CHCb0.2) were found to display significant decreases in neuronal-specific class III beta-tubulin. Interestingly, vincristine-selected cells exhibited increased levels of polymerized tubulin that were not due to alpha-tubulin and class I, II, or III beta-tubulin mutations. Expression levels of the microtubule-depolymerizing protein stathmin were significantly increased in BE/VCR10 cells. In contrast, levels of MAP2a and MAP2b were relatively unaltered. A marked decrease in the neuronal protein, MAP2c, was identified in the vincristine-selected cells and, to a lesser extent, in the colchicine-selected cells. This is the first report describing specific microtubule alterations in neuroblastoma cells resistant to tubulin-targeted agents. The results indicate a need to identify the factors responsible for resistance to tubulin-targeted agents in neuroblastoma so that improved and novel treatment strategies can be developed for this drug refractory disease.
AuthorsSima Don, Nicole M Verrills, Tracy Y E Liaw, Marjorie L M Liu, Murray D Norris, Michelle Haber, Maria Kavallaris
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 3 Issue 9 Pg. 1137-46 (Sep 2004) ISSN: 1535-7163 [Print] United States
PMID15367708 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • MAP2 protein, human
  • Microtubule Proteins
  • Microtubule-Associated Proteins
  • Phosphoproteins
  • Protein Isoforms
  • STMN1 protein, human
  • Stathmin
  • Tubulin
  • Paclitaxel
Topics
  • Drug Resistance, Neoplasm
  • Humans
  • Microtubule Proteins (analysis, metabolism)
  • Microtubule-Associated Proteins (analysis, metabolism)
  • Microtubules (drug effects, genetics, metabolism)
  • Mutation (genetics)
  • Neuroblastoma (drug therapy, metabolism, pathology)
  • Neurons (immunology, metabolism)
  • Paclitaxel (pharmacology)
  • Phosphoproteins (analysis, metabolism)
  • Protein Isoforms (analysis, metabolism)
  • Stathmin
  • Tubulin (analysis, genetics, metabolism)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: